• Most Popular
  • Most Shared

Lung cancer patients live longer with Alimta: study

WASHINGTON
Thu May 15, 2008 9:26pm EDT

WASHINGTON (Reuters) - Lung cancer patients who took Eli Lilly and Co's Alimta after finishing their normal course of chemotherapy lived 40 percent longer without any tumor progression than patients who took a placebo, researchers reported on Thursday.

Health  |  Stocks  |  Regulatory News

Preliminary results released ahead of the annual meeting of the American Society of Clinical Oncology showed Alimta extended progression-free survival by two months in patients given the drug as maintenance therapy.

Analysts say the results could greatly broaden the market for the already successful drug, with one group predicting an extra $1 billion from new uses for the drug.

"We believe the market opportunity for Alimta is substantial, offering potential upside versus our 2012 forecast of $1.7 billion," said Leerink Swann analyst Seamus Fernandez.

(Reporting by Maggie Fox)
Health
Stocks
Regulatory News


More from Reuters

Photo

RIM posts big gains in profit; shares surge

OTTAWA (Reuters) - BlackBerry maker Research In Motion reported a 58 percent jump in quarterly profit on Thursday, as sturdy demand from holiday shoppers helped fend off growing competition, sending its shares sharply higher.

» More Top News
President Barack Obama delivers remarks at Lehigh Carbon Community College in Allentown, Pennsylvania, December 4, 2009. REUTERS/Jim Young
Analysis:

Would you give him a B+ too?

"I told Michelle when we got here that in six months my poll numbers will start crashing," says President Obama. He's not worried -- yet.  Full Article 

Barack Obama
Bernd Debusmann
Bernd Debusmann:

Burning borrowed money

The Pentagon burns through $5 million in borrowed money every hour in Afghanistan and the amount is expected to more than double once additional troops are deployed.   Commentary 

Afghanistan